PortfoliosLab logoPortfoliosLab logo
PRME vs. TNGX
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

PRME vs. TNGX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Prime Medicine Inc. Common Stock (PRME) and Tango Therapeutics, Inc. (TNGX). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

PRME vs. TNGX - Yearly Performance Comparison


2026 (YTD)2025202420232022
PRME
Prime Medicine Inc. Common Stock
0.29%18.84%-67.04%-52.31%20.88%
TNGX
Tango Therapeutics, Inc.
136.12%186.73%-68.79%36.55%6.77%

Fundamentals

Market Cap

PRME:

$517.68M

TNGX:

$2.43B

EPS

PRME:

-$1.38

TNGX:

-$0.90

PS Ratio

PRME:

109.80

TNGX:

37.75

PB Ratio

PRME:

4.28

TNGX:

7.02

Total Revenue (TTM)

PRME:

$4.63M

TNGX:

$62.38M

Gross Profit (TTM)

PRME:

$0.00

TNGX:

$61.20M

EBITDA (TTM)

PRME:

-$195.76M

TNGX:

-$105.54M

Returns By Period

In the year-to-date period, PRME achieves a 0.29% return, which is significantly lower than TNGX's 136.12% return.


PRME

1D
10.48%
1M
-24.68%
YTD
0.29%
6M
-37.18%
1Y
74.87%
3Y*
-34.35%
5Y*
10Y*

TNGX

1D
8.90%
1M
87.79%
YTD
136.12%
6M
149.05%
1Y
1,427.01%
3Y*
74.31%
5Y*
13.76%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

PRME vs. TNGX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PRME
PRME Risk / Return Rank: 6868
Overall Rank
PRME Sharpe Ratio Rank: 6565
Sharpe Ratio Rank
PRME Sortino Ratio Rank: 7474
Sortino Ratio Rank
PRME Omega Ratio Rank: 6666
Omega Ratio Rank
PRME Calmar Ratio Rank: 7070
Calmar Ratio Rank
PRME Martin Ratio Rank: 6363
Martin Ratio Rank

TNGX
TNGX Risk / Return Rank: 100100
Overall Rank
TNGX Sharpe Ratio Rank: 100100
Sharpe Ratio Rank
TNGX Sortino Ratio Rank: 9999
Sortino Ratio Rank
TNGX Omega Ratio Rank: 9999
Omega Ratio Rank
TNGX Calmar Ratio Rank: 100100
Calmar Ratio Rank
TNGX Martin Ratio Rank: 100100
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PRME vs. TNGX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Prime Medicine Inc. Common Stock (PRME) and Tango Therapeutics, Inc. (TNGX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


PRMETNGXDifference

Sharpe ratio

Return per unit of total volatility

0.67

12.96

-12.29

Sortino ratio

Return per unit of downside risk

1.78

7.03

-5.25

Omega ratio

Gain probability vs. loss probability

1.19

1.83

-0.65

Calmar ratio

Return relative to maximum drawdown

1.42

48.73

-47.31

Martin ratio

Return relative to average drawdown

2.29

136.78

-134.49

PRME vs. TNGX - Sharpe Ratio Comparison

The current PRME Sharpe Ratio is 0.67, which is lower than the TNGX Sharpe Ratio of 12.96. The chart below compares the historical Sharpe Ratios of PRME and TNGX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


PRMETNGXDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.67

12.96

-12.29

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.14

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.39

0.15

-0.53

Correlation

The correlation between PRME and TNGX is 0.28, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

PRME vs. TNGX - Dividend Comparison

Neither PRME nor TNGX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

PRME vs. TNGX - Drawdown Comparison

The maximum PRME drawdown since its inception was -94.55%, roughly equal to the maximum TNGX drawdown of -93.64%. Use the drawdown chart below to compare losses from any high point for PRME and TNGX.


Loading graphics...

Drawdown Indicators


PRMETNGXDifference

Max Drawdown

Largest peak-to-trough decline

-94.55%

-93.64%

-0.91%

Max Drawdown (1Y)

Largest decline over 1 year

-52.77%

-27.15%

-25.62%

Max Drawdown (5Y)

Largest decline over 5 years

-93.64%

Current Drawdown

Current decline from peak

-83.52%

0.00%

-83.52%

Average Drawdown

Average peak-to-trough decline

-64.37%

-49.30%

-15.07%

Ulcer Index

Depth and duration of drawdowns from previous peaks

32.70%

9.67%

+23.03%

Volatility

PRME vs. TNGX - Volatility Comparison

The current volatility for Prime Medicine Inc. Common Stock (PRME) is 21.00%, while Tango Therapeutics, Inc. (TNGX) has a volatility of 33.52%. This indicates that PRME experiences smaller price fluctuations and is considered to be less risky than TNGX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


PRMETNGXDifference

Volatility (1M)

Calculated over the trailing 1-month period

21.00%

33.52%

-12.52%

Volatility (6M)

Calculated over the trailing 6-month period

66.76%

63.26%

+3.50%

Volatility (1Y)

Calculated over the trailing 1-year period

112.28%

111.67%

+0.61%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

91.01%

98.22%

-7.21%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

91.01%

93.71%

-2.70%

Financials

PRME vs. TNGX - Financials Comparison

This section allows you to compare key financial metrics between Prime Medicine Inc. Common Stock and Tango Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0010.00M20.00M30.00M40.00M50.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
838.00K
0
(PRME) Total Revenue
(TNGX) Total Revenue
Values in USD except per share items